- Home
- TPST vs IGC Comparison
TPST vs IGC Comparison
Compare TPST & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | IGC |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 33.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | IGC |
|---|---|---|
| Price | $2.92 | $0.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $12.50 | $4.13 |
| AVG Volume (30 Days) | 248.3K | ★ 553.7K |
| Earning Date | 11-05-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.87 | $0.25 |
| 52 Week High | $13.65 | $0.50 |
Technical Indicators
Market Signals| Indicator | TPST | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 24.91 | 47.79 |
| Support Level | $2.87 | $0.32 |
| Resistance Level | $3.23 | $0.36 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 7.95 | 60.45 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.